Controversy: For or against thyroid lobectomy in >1 cm differentiated thyroid cancer?

xlomafota13 shared this article with you from Inoreader Controversy: For or against thyroid lobectomy in >1 cm differentiated thyroid cancer? Via radioactive iodine Ann Endocrinol (Paris). 2021 Mar 20:S0003-4266(21)00029-9. doi: 10.1016/j.ando.2021.03.004. Online ahead of print. ABSTRACT In this controversy article, the respective advantages of lobectomy vs total thyroidectomy in differentiated thyroid cancers are argued. The authors conclude that lobectomy has the same oncological prognosis as thyroidectomy in terms of specific survival or recurrence, in case of low risk of recurrence (T1-2N0). However, as a precaution, and taking into accoun t current data, thyroidectomy is recommended that in N0 thyroid papillary cancers with aggressive subtype, with even minimal infiltration of perithyroid tissue and/or vascular invasion, and in N1 cancers with more than 5 lymphadenopathies or lymphadenopathies with a major axis greater than or equal to 0.2 cm. Other forms of papillary cancer should be treated with lobectomy, as risk of morbidity is low and hospital stay is short. Lobectomy allows reliable monitoring, especially by ultrasound. On the other hand, total thyroidectomy, despite a higher rate of surgical complications due to the risk of recurrent paralysis and permanent hypoparathyroidism, is nevertheless preferable to lobectomy, the latter not always avoiding hormone replacement therapy, in particular for more precise monitoring by thyroglobulin assay, which is uninterpretable after lobectomy but allows early diagnosis of local or metastatic recurrence and reduces mortality. Thus, in situations where the diagnostic criter ia for high-risk cancer are not rigorously determined or taken into account, thyroidectomy is recommended. In addition, it will remain preferable as long as the recommendations for administration of radioactive iodine do not change in favor of use reserved for high-risk cancers as in US guidelines. PMID:33757822 | DOI:10.1016/j.ando.2021.03.004 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.